Warren, Richard B, Kristian Reich, Eric L Simpson, Richard Langley, Antonio Costanzo, Hidehisa Saeki, Peter Almgren, Emilia Vacko, Melinda Gooderham, Mette Deleuran, Juan Francisco Silvestre, Stefan Weidinger, and Andrew Blauvelt. “3 Years of Tralokinumab Treatment Provides Long-Term Disease Control As Demonstrated by Clinically Meaningful Outcomes in Moderate-to-Severe Atopic Dermatitis”. SKIN The Journal of Cutaneous Medicine 6, no. 6 (November 16, 2022): s78. Accessed July 3, 2024. https://jofskin.org/33014/index.php/skin/article/view/1836.